摘要 |
The present disclosure provides methods of evaluating a subject, e.g., a subject at risk for or suffering from a pKal-mediated or bradykinin-mediated disorder, based on values (e.g., percentages) of intact and/or cleaved kininogen in a sample of the subject. Provided methods permit analysis of patients with plasma kallikrein-mediated angioedema (KMA), or other diseases mediated by pKal useful in the evaluation and treatment. Such methods can involve the use of a detection agent that preferentially binds cleaved kininogen or intact kininogen. |
申请人 |
DYAX CORP. |
发明人 |
SEXTON, DANIEL, J.;FAUCETTE, RYAN;KENNISTON, JON, A.;CONLEY, GREG;NIXON, ANDREW;TENHOOR, CHRISTOPHER;ADELMAN, BURT;CHYUNG, YUNG |